MCM2 is involved in subtyping and tamoxifen resistance of ERα‐positive breast cancer by acting as the downstream factor of ERα
Biotechnology Journal · 2024
DOI: 10.1002/biot.202300560 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, 2024. Verfasst von Sainan Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha, Minichromosome Maintenance Complex Component 2, Tamoxifen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Science Technology Department of Jilin Province, Department of Health and Family Planning Commission of Jilin Province, Bethune Department of Medicine in Jilin University, Bethune Plan.
Abstract (Originalsprache)
Tamoxifen (TAM) resistance is finally developed in over 40% of patients with estrogen receptor α‐positive breast cancer (ERα + ‐BC), documenting that discovering new molecular subtype is needed to confer perception to the heterogeneity of ERα + ‐BC. We obtained representative gene sets subtyping ERα + ‐BC using gene set variation analysis (GSVA), non‐negative matrix factorization (NMF), and COX regression methods on the basis of METABRIC, TCGA, and GEO databases. Furthermore, the risk score of ERα + ‐BC subtyping was established using least absolute shrinkage and selection operator (LASSO) regression on the basis of genes in the representative gene sets, thereby generating the two subtypes of ERα + ‐BC. We further found that minichromosome maintenance complex component 2 ( MCM2 ) functioned as the hub gene subtyping ERα + ‐BC using GO, KEGG, and MCODE. MCM2 expression was capable for specifically predicting 1‐year overall survival (OS) of ERα + ‐BC and correlated with T stage, AJCC stage, and tamoxifen (TAM) sensitivity of ERα + ‐BC. The downregulation of MCM2 expression inhibited proliferation, migration, and invasion of TAM‐resistant cells and promoted G0/G1 arrest. Altogether, tamoxifen resistance entails that MCM2 is a hub gene subtyping ERα + ‐BC, providing a novel dimension for discovering a potential target of TAM‐resistant BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China.
- NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China.
- Institute of Translational Medicine, the First Hospital of Jilin University, Changchun, China.
ORCID-Profile: Yawen Liu
Förderung
- Science Technology Department of Jilin Province
- Department of Health and Family Planning Commission of Jilin Province
- Bethune Department of Medicine in Jilin University, Bethune Plan
- Graduate school of Jilin University, Graduate Innovative Research Program
- National Natural Science Foundation of China
Zitieren
APA
Liu, S., Liang, Z., Wang, Y., Ren, Y., Gu, Y., Qiao, Y., He, H., Li, Y., Cheng, Y., & Liu, Y. (2024). MCM2 is involved in subtyping and tamoxifen resistance of ERα‐positive breast cancer by acting as the downstream factor of ERα. Biotechnology Journal. https://doi.org/10.1002/biot.202300560
Vancouver
Liu S, Liang Z, Wang Y, Ren Y, Gu Y, Qiao Y, et al. MCM2 is involved in subtyping and tamoxifen resistance of ERα‐positive breast cancer by acting as the downstream factor of ERα. Biotechnology Journal. 2024. doi:10.1002/biot.202300560
BibTeX
@article{Liu2024,
author = {Liu, Sainan and Liang, Zhuoshuai and Wang, Yujian and Ren, Yaxuan and Gu, Yulu and Qiao, Yichun and He, Huan and Li, Yong and Cheng, Yi and Liu, Yawen},
title = {MCM2 is involved in subtyping and tamoxifen resistance of ERα‐positive breast cancer by acting as the downstream factor of ERα},
journal = {Biotechnology Journal},
year = {2024},
doi = {10.1002/biot.202300560}
}
EUVIMED